EDIT analyst estimates
Editas Medicine (EDIT) analyst ratings, the average price target and its range, and every firm's latest call.
EDIT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 8, 2026 | Wells Fargo | Wells Fargo upgrades Editas Medicine after EDIT-401 study gets green light | $6.00 |
| Sep 23, 2026 | Guggenheim | Guggenheim Upgrades Editas Medicine (EDIT) to Buy | $5.00 |
| May 5, 2026 | Chardan Capital | Editas Medicine price target raised to $4 from $3.50 at Chardan | $4.00 |
| Mar 9, 2026 | Robert W. Baird | Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings | $6.00 |
| Nov 5, 2024 | Barclays | Editas Medicine (EDIT) PT Lowered to $5 at Barclays | $5.00 |
| Oct 23, 2024 | Wells Fargo | Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo | $9.00 |
| Oct 22, 2024 | Robert W. Baird | Editas Medicine (EDIT) PT Lowered to $10 at Baird | $10.00 |
| Aug 8, 2024 | Bank of America Securities | BofA Securities Upgrades Editas Medicine (EDIT) to Buy | $15.00 |
| Aug 8, 2024 | Truist Financial | Editas Medicine (EDIT) PT Lowered to $12 at Truist Securities | $12.00 |
| May 30, 2024 | Evercore ISI | Editas Medicine (EDIT) PT Lowered to $7 at Evercore ISI | $7.00 |
| May 9, 2024 | Morgan Stanley | Morgan Stanley Upgrades Editas Medicine (EDIT) to Equalweight | $7.00 |
| Sep 28, 2023 | Stifel Nicolaus | Stifel Upgrades Editas Medicine (EDIT) to Buy, 'Difficult To Justify Current Valuation' | $17.00 |
| Dec 13, 2022 | Citigroup | Citigroup Initiates Coverage On Editas Medicine with Neutral Rating, Announces Price Target of $11 | $11.00 |
| Nov 18, 2022 | RBC Capital | RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $14 | $14.00 |
| Nov 18, 2022 | Morgan Stanley | Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $8 | $8.00 |
- 4 firms rate EDIT: 4 buy, 0 hold, 0 sell.
- The average price target is $5.50 from None analysts, from $5.00 to $6.00.
Updated 2026-11-10 04:45 UTC